30th Annual ROTH Conference
March 11-14, 2018
Ritz Carlton, Dana Point, CA
ROTH Capital Partners' 30th Annual Conference is one of the largest of its kind in the United States. With roughly 500 participating companies and over 4,000 attendees, Roth will feature presentations from hundreds of public and private companies in a variety of sectors including health care; technology, Internet and media; cleantech, industrial growth and solar; consumer; oil and gas/mining and minerals; and business services. The three-and-a-half day event will include company presentations and small group meetings, as well as panels, entertainment and more. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space. For more information visit www.Roth.com
22nd Century (XXII)
22nd Century (NYSE: XXII) is a plant biotech company providing technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants and the level of cannabinoids in cannabis plants to be decreased or increased through genetic engineering and plant breeding. The company develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. For more information, visit the company's website at www.xxiicentury.com.
AcelRx Pharmaceuticals (ACRX)
AcelRx Pharmaceuticals (NASDAQ: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The company employs its proprietary, non-invasive sublingual formulation technology that delivers sufentanil with consistent pharmacokinetic profiles. The company's two product candidates are DSUVIA™ (known as DZUVEO outside the United States) intended to treat moderate-to-severe acute pain in medically supervised settings, and ZALVISO® which is being developed as a patient-controlled analgesia (PCA) system to reduce moderate-to-severe acute pain in medically supervised settings. For more information, visit the company's website at www.acelrx.com.
Acer Therapeutics (ACER)
Acer Therapeutics (NASDAQ: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for patients with serious rare and ultra-rare diseases with critical unmet medical need. The company's late-stage clinical pipeline includes EDSIVO™ for vascular Ehlers-Danlos syndrome (vEDS) and ACER-001 for urea cycle disorders (UCD) and Maple Syrup Urine Disease (MSUD). Currently, there are no FDA-approved drugs for vEDS and MSUD and limited options for UCD, which together impact more than 4,000 patients in the United States. Acer's product candidates have clinical proof-of-concept and mechanistic differentiation, and Acer intends to seek approval for them in the U.S. by using the regulatory pathway established under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act which enables the applicant to utilize third-party data, which is expected to expedite the preparation, submission, and potential approval of a marketing application. For more information, visit the company's website at www.acertx.com.
ACM Research (ACMR)
ACM Research (NASDAQ: ACMR) develops wet processing technology and products for the semiconductor industry. Since being founded in 1998 in Silicon Valley, the company has produced equipment for a range of applications in IC manufacturing and wafer level packaging — with a special focus on cleaning technologies for advanced semiconductor devices. Semiconductor manufacturers can use the company's single-wafer wet cleaning equipment in numerous manufacturing steps to remove particles, contaminants and other random defects, and thereby improve product yield, in fabricating advanced integrated circuits. For more information, visit the company's website at www.acmrcsh.com.
Acme United (ACU)
Acme United (NYSE: ACU) is a worldwide supplier of innovative cutting, measuring first aid and sharpening products to the school, home, office, sporting goods, hardware and industrial markets. Its brands include Westcott®, Clauss®, Camillus®, Cuda®, PhysiciansCare®, First Aid Only®, Pac-Kit®, DMT® and Spill Magic®. The company's operations are in the United States, Canada, Europe (located in Germany) and Asia (located in Hong Kong and China.) For more information, visit the company's website at www.acmeunited.com.
Actinium Pharmaceuticals (ATNM)
Actinium Pharmaceuticals (NYSE: ATNM) is a clinical-stage biopharmaceutical company engaged in developing innovative targeted payload immunotherapies for the treatment of advanced cancers. The company's radio-immunotherapy product candidates are based on the combination of the cancer targeting precision of monoclonal antibodies (mAb) that seek out specific types of cells combined with the cytotoxic killing power of radioisotopes that unleash their energy once they have reached their target. The company's product pipeline includes Iomab-B CD45 to treat myeloablation prior to Bone Marrow Transplant (BMT), patients over age 55 with relapsed or refractory AML and induction and conditioning agent prior to a BMT1; Actimab-A (f.d.) CD33 to treat AML and newly diagnosed patients with AML over age 60; Actimab-M CD33 to treat multiple myeloma and relapsed or refractory patients age 18 and above; Actimab-MDS CD33 to treat myelodysplastic syndrome (MDS) and myeloablation prior to BMT for high-risk MDS patients with a p53 genetic mutation; Actinium-225 conjugated to daratumumab, a CD38 targeting agent to treat multiple myeloma; Actimab-C to treat colon cancer; Actimab-P to treat prostate cancer; and Actimab-Br to treat brain cancer. For more information, visit the company's website at www.actiniumpharma.com.
Acushnet Holdings (GOLF)
Acushnet Holdings (NYSE: GOLF) is engaged in the design, development, manufacture and distribution of quality, performance-driven golf products. The company's mission since 1932 has remained consistent, striving to be the performance and quality leader in every golf product category in which it competes. Today, the company is the steward of two of the most revered brands in golf — Titleist, a golf performance equipment brand, and FootJoy, a golf performance wearables brands. For more information, visit the company's website at www.acushnetholdingscorp.com.
Adesto Technologies (IOTS)
Adesto Technologies (NASDAQ: IOTS) is a provider of application-specific, ultra-low power, smart non-volatile memory products. The company has designed and built a portfolio of innovative products with intelligent features to conserve energy and enhance performance, including Fusion Serial Flash, DataFlash®, EcoXiP™ and products based on its trademark resistive RAM technology called Conductive Bridging RAM (CBRAM®). CBRAM® is a breakthrough technology platform that enables 100 times less energy consumption than today's flash memory technologies as well as delivering enhanced performance. For more information, visit the company's website at www.adestotech.com.
ADOMANI (NASDAQ: ADOM) is a provider of zero-emission electric and replacement drivetrains that is focused on reducing the total cost of vehicle ownership. ADOMANI designs its drivetrain systems to help fleet operators unlock the benefits of green technology and address the challenges of traditional fuel price instability and local, state and federal environmental regulatory compliance. ADOMANI designs advanced zero-emission electric drivetrain systems for integration in new school buses and medium-to-heavy-duty commercial fleet vehicles. For more information, visit the company's website at www.adomanielectric.com.
Agilysys (NASDAQ: AGYS) provides innovative software and services for point-of-sale (POS), property management, reservation and table management, inventory and procurement, workforce management, analytics, document management, and mobile and wireless solutions to the hospitality industry. The company's advanced products and services enable operators to streamline operations, improve efficiency and understand customer needs to deliver a superior overall guest experience. The company serves major market sectors including corporate foodservice management and restaurants, gaming, hotels, resorts, universities, and healthcare. Agilysys operates across North America, Europe, Asia-Pacific, and India with headquarters located in Alpharetta, GA. For more information, visit the company's website at www.agilysys.com.
Allergan plc (AGN)
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories. For more information, visit the company's website at www.allergan.com.
AgroFresh Solutions (AGFS)
AgroFresh Solutions (NASDAQ: AGFS) provides innovative data-driven specialty solutions aimed at enabling growers and packers of fresh produce to preserve and enhance the freshness, quality and value of the produce. Additionally, the company's services enable growers and packers to maximize the percentage of produce supplied to the market relative to the amount of produce grown. Its flagship product is the SmartFresh™ Quality System, a freshness protection technology proven to maintain firmness, texture and appearance of fruits during storage and transport. SmartFresh is currently commercialized in over 40 countries worldwide. Additionally, the company has various solutions and application technologies that extend its footprint to other steps of the global produce supply chain, such as Harvista™, RipeLock™, and LandSpring™. For more information, visit the company's website at www.AgroFresh.com.
Aimmune Therapeutics (AIMT)
Aimmune Therapeutics (NASDAQ AIMT) is a clinical-stage biopharmaceutical company developing treatments for potentially life-threatening food allergies. The company's Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA's Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, visit the company's website at www.aimmune.com.
Air Industries Group (AIRI)
Air Industries Group (NYSE: AIRI) is an integrated manufacturer of precision equipment assemblies and components for leading aerospace and defense prime contractors. Air Industries operates in three segments: Complex Machining of aircraft landing gear and flight controls, Aerostructures & Electronics, and Turbine & Engine products. For more information, visit the company's website at www.airindustriesgroup.com.
Airborne Wireless Network (ABWN)
Airborne Wireless Network (OTCQB: ABWN) is a development stage company focused on developing, marketing, and licensing a high-speed broadband airborne wireless network by linking commercial aircrafts in flight. The company intends to create a digital information highway in the sky by developing a way for aircrafts participating in the network to act as an airborne repeater or router, sending and receiving broadband signals from one aircraft to the next. The company believes that once the network is developed and fully implemented, it may have a broad spectrum of applications. Once developed, the network is anticipated to provide low cost, high-speed connectivity to rural areas, island nations, ships at sea, oil platforms, in addition to connectivity to commercial and private aircraft in flight. For more information, visit the company's website at www.airbornewirelessnetwork.com.
AIT Therapeutics (AITB)
AIT Therapeutics (OTC: AITB) is a clinical-stage biopharmaceutical company engaged in developing treatments for serious lung infections and pulmonary hypertension using nitric oxide ("NO"). AIT Therapeutics also utilizes its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. Additionally, the company is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and for nontuberculous mycobacteria. For more information, visit the company's website at www.AIT-Pharm.com.
Akoustis Technologies (AKTS)
Akoustis Technologies (OTC: AKTS) is a high-tech Radio Frequency ("RF") filter solutions company that designs and manufactures various RF filters enabling the RF front-end of mobile wireless devices, such as smartphones and tablets. Akoustis focuses on manufacturing and commercializing its patent-pending Bulk ONE® acoustic wave technology to address the frequency-selectivity requirements in mobile smartphones, enhancing the efficiency and signal quality of mobile wireless devices and enabling The Internet of Things. For more information, visit the company's website at www.akoustis.com.
Alarm.com (NASDAQ: ALRM) is a leading platform for an intelligently connected property. Millions of people use Alarm.com's technology to monitor and control their property from anywhere. Centered on security and remote monitoring, the company's platform addresses a wide range of market needs and enables application-based control for a growing variety of Internet of Things (IoT) devices. Security, video monitoring, intelligent automation and energy management solutions are available through a network of thousands of professional service providers in North America and around the globe. For more information, visit the company's website at www.alarm.com.
Albireo Pharma (ALBO)
Albireo Pharma (NASDAQ: ALBO) is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's clinical pipeline includes a Phase 3 product candidate for the treatment of patients with the orphan pediatric liver disease known as progressive familial intrahepatic cholestasis, as well as a Phase 2 product candidate. In addition, Albireo's elobixibat, approved in Japan for the treatment of chronic constipation, is the first IBAT inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. For more information, visit the company's website at www.albireopharma.com.
Altimmune (NASDAQ: ALT) is a clinical-stage biotechnology company that designs and develops immunotherapeutic products. The company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's product pipeline includes NasoVAX, a phase 2 seasonal influenza vaccine candidate, and HepTcell, a phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. Additionally, Altimmune has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. For more information, visit the company's website at www.altimmune.com.
Ameresco (NYSE: AMRC) is an independent provider of comprehensive services, energy efficiency, infrastructure upgrades, asset sustainability and renewable energy solutions for businesses and organizations throughout North America and Europe. The company's sustainability services include upgrades to a facility's energy infrastructure and the development, construction and operation of renewable energy plants. Founded in 2000, Ameresco has completed energy saving, environmentally responsible projects with federal, state and local governments, healthcare and educational institutions, housing authorities, and commercial and industrial customers. With its corporate headquarters in Framingham, MA, Ameresco has more than 1,000 employees in the United States, Canada, and the United Kingdom. For more information, visit the company's website at www.ameresco.com.
American Superconductor (AMSC)
American Superconductor (NASDAQ: AMSC) generates ideas, technologies and solutions to meet the world's demand for smarter, cleaner … better energy™. Through its Windtec™ Solutions, the company provides wind turbine electronic controls and systems, designs and engineering services that reduce the cost of wind energy. Through its Gridtec™ Solutions, the company provides the engineering planning services and advanced grid systems that optimize network reliability, efficiency and performance. The company's solutions are now powering gigawatts of renewable energy globally and are enhancing the performance and reliability of power networks in more than a dozen countries. Founded in 1987, AMSC is headquartered near Boston, Massachusetts with operations in Asia, Australia, Europe and North America. For more information, visit the company's website at www.amsc.com.
American Vanguard (AVD)
American Vanguard (NYSE: AVD) is a diversified specialty and agricultural products company that develops and markets products for crop protection and management, turf and ornamentals management and public and animal health. The company employs a strategy of acquiring or licensing both new and well-established product lines that serve numerous high valued market niches. New product development and international expansion also provide an additional stimulus for growth. For more information, visit the company's website at www.american-vanguard.com.
Americas Silver (USAS)
Americas Silver (TSX: USA) (NYSE: USAS) is a silver mining company engaged in the acquisition, evaluation, exploration, development, and operation of precious metals mineral properties in North America. The company focused on growth in precious metals from its existing asset base and execution of targeted accretive acquisitions. It owns and operates the Cosalá Operations in Sinaloa, Mexico and the Galena Mine Complex in Idaho, USA. Additionally, the company has acquired an option on the San Felipe development project in Sonora, Mexico. For more information, visit the company's website at www.americassilvercorp.com.
Amtech Systems (ASYS)
Amtech Systems (NASDAQ: ASYS) is a global supplier of advanced thermal processing equipment to the solar, semiconductor / electronics, and LED manufacturing markets. Amtech's equipment includes diffusion, ALD and PECVD systems and solder reflow systems. Amtech also supplies wafer handling automation and polishing equipment and related consumable products. The company's wafer handling, thermal processing and consumable products currently address the diffusion, oxidation, and deposition steps used in the fabrication of P-multi, P-mono, N-Pert and PERC solar cells, LEDs, semiconductors, MEMS, printed circuit boards, semiconductor packaging, and the polishing of newly sliced sapphire and silicon wafers. For more information, visit the company's website at www.amtechsystems.com.
Anavex Life Sciences (AVXL)
Anavex Life Sciences (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company engaged in the development of drug candidates for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system ("CNS") diseases, pain and various types of cancer. ANAVEX®2-73, the company's lead drug candidate, has successfully completed a phase 2 clinical trial for Alzheimer's disease in which the drug exhibited the potential to treat additional CNS disorders, including epilepsy. Additionally, the company has received a research grant from the Michael J. Fox Foundation for Parkinson's Research to develop ANAVEX®2-73 for the treatment of Parkinson's disease. The company's product pipeline also includes another treatment for Alzheimer's, ANAVEX®3-71, a promising preclinical drug candidate that has demonstrated disease modifications. For more information, visit the company's website at www.anavex.com.
Anthera Pharmaceuticals (ANTH)
Anthera Pharmaceuticals (NASDAQ: ANTH) is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal diseases. The company has two product candidates in development: Sollpura, a novel, biotechnology-derived pancreatic enzyme replacement therapy for the potential treatment of exocrine pancreatic insufficiency due to cystic fibrosis; and Blisibimod, a BAFF inhibitor for the potential treatment of IgA nephropathy. For more information, visit the company's website at www.anthera.com.
Apollo Endosurgery (APEN)
Apollo Endosurgery (NASDAQ: APEN) is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. The company's device-based therapies are an alternative to invasive surgical procedures, consequently decreasing complication rates and reducing total healthcare costs. Apollo's products are offered in over 80 countries today. For more information, visit the company's website at www.apolloendo.com.
Applied DNA Sciences (APDN)
Applied DNA Sciences (NASDAQ: APDN) provides molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics. The company's proprietary DNA-based "CertainT™" platform can be used to identify, tag, test and track products to help assure authenticity, origin, traceability, sustainability and quality of products. SigNature® DNA describes the core technology ingredient that is at the heart of a family of uncopiable, security and authentication solutions such as SigNature® T and fiberTyping®, targeted toward textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and loss prevention, and digitalDNA®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction. For more information, visit the company's website at www.adnas.com.
Aptevo Therapeutics (APVO)
Aptevo Therapeutics (NASDAQ: APVO) is a clinical-stage biotechnology company based in Seattle, Washington focused on novel oncology and hematology therapeutics to meaningfully improve patients' lives. The company's core technology is the ADAPTIR™ (modular protein technology) platform. IXINITY®, the company's commercial product, has been approved and marketed in the United States for the treatment of Hemophilia B. Aptevo has two ADAPTIR antibody candidates currently in clinical development and a broad pipeline of novel investigational-stage bispecific antibody candidates focused in immuno-oncology and autoimmune disease and inflammation. For more information, visit the company's website at www.aptevotherapeutics.com.
Aptose Biosciences (APTO)
Aptose Biosciences (NASDAQ: APTO) is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for its products. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For more information, visit the company's website at www.aptose.com.
AquaVenture (NYSE: WAAS) is a multinational provider of WAAS™ solutions that provide customers a reliable and cost-effective source of clean drinking and process water primarily under long-term contracts that minimize capital investment by the customer. AquaVenture is composed of two operating platforms: Quench, a U.S.-based provider of Point-of-Use filtered water systems and related services to approximately 40,000 institutional and commercial customers; and Seven Seas Water, a multinational provider of desalination and wastewater treatment solutions, providing 8 billion gallons of potable, high purity industrial grade and ultra-pure water per year to governmental, municipal, industrial and hospitality customers. For more information, visit the company's website at www.aquaventure.com.
Arch Therapeutics (ARTH)
Arch Therapeutics (OTC: ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma, and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include the AC5™ Topical Gel and the AC5™ Surgical Hemostatic Device. For more information, visit the company's website at www.archtherapeutics.com.
Arcimoto (NASDAQ: FUV) engages in the development, design and manufacture of electric vehicles. The company is engaged in creating new technologies and patterns of mobility that together raise the bar for environmental efficiency and affordability. Arcimoto's fun utility vehicle ("FUV") is an affordable and performance-packed electric vehicle that is suitable for the daily driver. The vehicle is available for pre-order today with a target purchase price of $11,900. For more information, visit the company's website at www.arcimoto.com.
ArQule (NASDAQ: ARQL) is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. The company's mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need to significantly extend and improve the lives of patients. The company's clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations. The company's proprietary pipeline includes Derazantinib, Miransertib (ARQ 092), ARQ 751 and ARQ 761. Additionally, ArQule has advanced ARQ 531 to phase 1 for patients with B-cell malignancies refractory to other therapeutic options. ArQule's current discovery efforts are focused on identifying and developing novel kinase inhibitors, leveraging the company's proprietary library of compounds. For more information, visit the company's website at www.arqule.com.
Artemis Therapeutics (ATMS)
Artemis Therapeutics (OTC: ATMS) is a clinical-stage biopharmaceutical company focused on the development of new therapies for the treatment and prevention of severe and life-threatening infectious diseases. The company's lead product candidate, Artemisone, is a unique, synthetic artemisinin derivative with potent anti-viral and anti-parasitic properties. The company currently is evaluating Artemisone for the treatment of p. falciparum malaria and human cytomegalovirus (CMV) infections, including stem cell transplant CMV and congenital CMV. Artemis also plans to evaluate Artemisone for the treatment of additional viral and parasitic diseases. For more information, visit the company's website at www.artemis-therapeutics.com.
Aspen Group (ASPU)
Aspen Group (NASDAQ: ASPU) is a post-secondary education company. Aspen University's mission is to offer any motivated college-worthy student the opportunity to receive a high quality, responsibly priced distance-learning education for the purpose of achieving sustainable economic and social benefits for themselves and their families. Aspen is dedicated to providing the highest quality education experiences taught by top-tier faculty; 54% of Aspen University's faculty hold doctoral degrees. For more information, visit the company's website at www.aspen.edu.
Assure Holdings (ARHH)
Assure Holdings (OTCQB: ARHH) works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. Although the company focuses primarily on supporting spinal and vascular surgeries, plans are in place to support other classes of medicine that rely on the standard of care that intraoperative neuromonitoring provides. For more information, visit the company's website at www.assureneuromonitoring.com.
Asure Software (ASUR)
Asure Software (NASDAQ: ASUR) offers solutions designed to help organizations of all sizes and complexities build companies of the future. The company's cloud platforms enable more than 80,000 clients worldwide an improved way to manage their people and space in a mobile, digital, multi-generational, and global workplace. Asure Software's offerings include a fully-integrated HCM platform, flexible benefits and compliance administration, HR consulting, and time and labor management as well as a full suite of workspace management solutions for conference room scheduling, desk sharing programs, and real estate optimization. For more information, visit the company's website at www.asuresoftware.com.
ASV Holdings (ASV)
ASV Holdings (NASDAQ: ASV) designs and manufactures a comprehensive suite of high-quality compact track and skid steer loaders, and also sells OEM equipment and aftermarket parts. The company's patented Posi-Track rubber tracked, multi-level suspension undercarriage system delivers a competitive market differentiator for its Compact Track Loader ("CTL") product line with brand attributes of power, performance and serviceability. ASV's wheeled Skid Steer Loaders ("SSLs") also share the common brand attributes. ASV equipment is sold through an independent dealer network throughout North America, Australia and New Zealand. For more information, visit the company's website at www.asvi.com.
Attunity (NASDAQ: ATTU) provides data integration and big data management software solutions that enable availability, delivery, and, management of data across heterogeneous enterprise platforms, organizations, and the cloud. The company's software solutions are comprised of data replication and distribution, test data management, change data capture, data connectivity, enterprise file replication, managed file transfer, data warehouse automation, data usage analytics, and cloud data delivery. Headquartered in Boston, Attunity serves its customers via offices in North America, Europe and Asia Pacific and through a network of local partners. For more information, visit the company's website at www.attunity.com.
Aurora Cannabis (ACBFF)
Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB) produces and distributes medical marijuana products in Canada. Aurora's wholly owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis through Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). Aurora also owns Berlin-based Pedanios GmbH, a wholesale importer, exporter and distributor of medical cannabis in the European Union. Additionally, the company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc., and has a strategic investment in Hempco Food and Fiber Inc. The company also has a stake in two other licensed producers, with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, and a 17.62% stake in Canadian producer The Green Organic Dutchman Ltd. For more information, visit the company's website at www.auroramj.com.
Auryn Resources (AUG)
Auryn Resources (TSX: AUG) (NYSE: AUG) is a junior exploration company that engages in the acquisition, exploration, and development of resource properties in Canada and Peru. The company is focused on delivering shareholder value through project acquisition and development. Auryn's management team is very experienced with an impressive track record of success and has assembled an extensive technical team as well as a premier gold exploration portfolio. Auryn is focused on scalable high-grade gold deposits in established mining jurisdictions, which include the Committee Bay and Gibson MacQuoid gold projects located in Nunavut, the Homestake Ridge gold project in British Columbia and a portfolio of gold projects in southern Peru, through Corisur Peru SAC. For more information, visit the company's website at www.aurynresources.com.
Avadel Pharmaceuticals (AVDL)
Avadel Pharmaceuticals (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to develop. Avadel focuses primarily on providing solutions for overlooked and unmet medical needs. The company utilizes its proprietary drug delivery technology and in-licensing or acquiring new products to ultimately help patients see better results. Avadel currently markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, visit the company's website at www.avadel.com.
Avid Bioservices (CDMO)
Avid Bioservices (NASDAQ: CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. For more information, visit the company's website at www.avidbio.com.
AxoGen (NASDAQ: AXGN) is engaged in innovative surgical solutions for peripheral nerve injuries. AxoGen's portfolio of products includes Avance®Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and Avive™ Soft Tissue Membrane. Along with these core surgical products, the company also offers AxoTouch™ Two-Point Discriminator and AcroVal™ Neurosensory & Motor Testing System. AxoGen's suite of evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several European and international countries. For more information, visit the company's website at www.axogeninc.com.
Azure Power Global (AZRE)
Azure Power Global (NYSE: AZRE) is an independent solar power producer. The company developed India's first private utility scale solar project in 2009 and has been a developer, constructor and operator of utility scale, micro-grid and rooftop solar projects since its inception in 2008. With its in-house engineering, procurement and construction expertise and advanced in-house operations and maintenance capability, Azure Power manages the entire development and operation process, providing low-cost solar power solutions to customers throughout India. For more information, visit the company's website at www.azurepower.com.
AzurRx BioPharma (AZRX)
AzurRx BioPharma (NASDAQ: AZRX) is a biopharmaceutical company engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company's lead development program MS1819 recombinant lipase for exocrine pancreatic insufficiency and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. For more information, visit the company's website at www.azurrx.com.
Ballard Power Systems (BLDP)
Ballard Power Systems (NASDAQ: BLDP) provides clean energy products that reduce customer costs and risks, and helps customers solve difficult technical and business challenges in their fuel cell programs. The company goal is to be the leading global provider of innovative clean energy solutions offering superior performance at a reduced operating cost. For more information, visit the company's website at www.ballard.com.
Barfresh Food Group (BRFH)
Barfresh Food Group (OTC: BRFH) is a developer, manufacturer and distributor of ready-to-blend beverages, including smoothies, shakes and frappes, primarily for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient and without waste. Barfresh has an exclusive distribution partnership with the leading food distributor in North America. For more information, visit the company's website at www.barfresh.com.
Barrett Business Services (BBSI)
Barrett Business Services (NASDAQ: BBSI) is a provider of business management solutions, merging human resource outsourcing and professional management consulting to create a unique operational platform that distinguishes it from competitors. The company's integrated platform is built upon expertise in payroll processing, employee benefits, workers' compensation coverage, risk management and workplace safety programs, and human resource administration. BBSI's partnerships help businesses of all sizes improve the efficiency of their operations. For more information, visit the company's website at www.barrettbusiness.com.
Benitec Biopharma (BNTC)
Benitec Biopharma (NASDAQ: BNTC) is a biotechnology company developing innovative therapeutics for chronic and life-threatening human diseases based on its patented gene-silencing technology, DNA-directed RNA interference or 'expressed RNAi' ("ddRNAi"). Based in Sydney, Australia with laboratories in Hayward, California and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for conditions including hepatitis B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa. For more information, visit the company's website at www.benitec.com.
BG Staffing (BGSF)
BG Staffing (NYSE: BGSF) provides staffing services to a variety of industries through its various divisions. The company is primarily a professional temporary staffing platform that has integrated several regional and national brands achieving scalable growth. It was ranked as the top 60th largest U.S. staffing company in 2016 and was named the 71st fastest growing staffing company in the country in 2016 by Staffing Industry Analysts. The company's acquisition philosophy is one that not only brings financial growth, but retention of unique and dedicated talent within the companies. The company employs a strong, tenured management team while building value for its investors. For more information, visit the company's website at www.bgstaffing.com.
Bio-Path Holdings (BPTH)
Bio-Path Holdings (NASDAQ: BPTH) is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a phase 2 study for blood cancers as well as in preclinical studies for solid tumors. Additionally, the company's product pipeline includes BP1002, targeting the Bcl2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors. For more information, visit the company's website at www.biopathholdings.com.
Biocept (NASDAQ: BIOC) is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. By leveraging its proprietary liquid biopsy technology, the company provides physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform identifies and analyzes tumor-associated molecular markers in both circulating tumor cells and in circulating tumor DNA. The platform has demonstrated the ability to identify cancer mutations and alterations to notify physicians about a patient's disease and therapeutic options. For more information, visit the company's website at www.biocept.com.
BioDelivery Sciences International (BDSI)
BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company with a primary focus in the areas of pain management and addiction medicine. The company employs drug delivery technologies, such as its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology, to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. The company also works in partnership with third parties to develop and commercialize these products. Current marketed products and products in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain and opioid dependence. BDSI's headquarters is in Raleigh, North Carolina. For more information, visit the company's website at www.bdsi.com.
BioPharmX (NYSE: BPMX) is a specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology, aesthetics and women's health. BioPharmX aims to bring new products to market by identifying optimal delivery mechanisms and alternative applications for FDA-approved or well characterized active pharmaceutical ingredients (APIs) and biological materials. The Silicon Valley-based company employs a market-driven approach to recognize the restrictions of current treatment options and work to develop products that may address these limitations in areas of efficacy, safety, or patient experience. For more information, visit the company's website at www.BioPharmX.com.
Blue Bird (BLBD)
Blue Bird (NASDAQ: BLBD) is an independent designer and manufacturer of school buses, with more than 550,000 buses sold since its formation in 1927 and approximately 180,000 buses in operation today. Blue Bird focuses on the design, engineering, manufacture and sale of school buses and related parts. The company is the only manufacturer of chassis and body production specifically designed for school bus applications, and offers alternative fuel applications with its propane-powered and compressed natural gas-powered school buses. Blue Bird manufactures school buses at two facilities in Fort Valley, Georgia. Its Micro Bird joint venture operates a manufacturing facility in Drummondville, Quebec, Canada. Service and after-market parts are distributed from Blue Bird's parts distribution center located in Delaware, Ohio. For more information, visit the company's website at www.blue-bird.com.
Boxlight (NASDAQ: BOXL) provides various technology and STEM solutions for the worldwide education market. The company offers educators products suitable for a modern classroom, resulting in improved student engagement and positive learning outcomes. Boxlight develops, sells and services its integrated, interactive solution suite of software, classroom technologies, professional development, and support services. The company also provides educators with thousands of free lesson plans and activities via MimioConnect®. For more information, visit the company's website at www.boxlight.com.
Broadwind Energy (BWEN)
Broadwind Energy (NASDAQ: BWEN) provides components and gearing as well as other specialized applications for customers in the clean tech, energy and infrastructure markets. The company is a precision manufacturer of these structures, equipment and components. With facilities throughout the U.S., the company is committed to helping customers maximize performance of their investments in a quicker, easier and smarter way. For more information, visit the company's website at www.bwen.com.
Callaway Golf (ELY)
Callaway Golf (NYSE:ELY) is focused on creating products designed to make every golfer a better golfer. Callaway Golf Company manufactures and sells golf clubs and golf balls, and sells bags, accessories and apparel in the golf and lifestyle categories, under the Callaway Golf®, Odyssey®, OGIO and TravisMathew brands worldwide. For more information please visit www.callawaygolf.com, www.odysseygolf.com, www.OGIO.com, and www.travismathew.com.
Can-Fite BioPharma (CANF)
Can-Fite BioPharma (NYSE: CANF) is an advanced clinical stage drug development company with a platform technology that is intended to address multi-billion-dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. Piclidenoson, Can-Fite's lead drug candidate, is currently in a phase 3 trial for rheumatoid arthritis and is expected to enter a phase 3 trial for psoriasis during 2018. The company's liver cancer drug, Namodenoson, is in phase 2 trials for the most common form of liver cancer, hepatocellular carcinoma ("HCC"), and for the treatment of non-alcoholic steatohepatitis ("NASH"). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the FDA. The company's third drug candidate, CF602, has demonstrated efficacy in the treatment of erectile dysfunction in preclinical studies and the company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. For more information, visit the company's website at www.can-fite.com.
Canopy Growth (TWMFJ)
Canopy Growth (TSE: WEED) (OTC: TWMFJ) is engaged in the business of producing and selling legal marijuana in the Canadian medical market and is also focusing on producing and selling marijuana in the recreational market. The company operates seven cannabis production sites with over 665,000 square feet of production capacity and offers distinct brands and curated cannabis varieties in dried, oil and soft gel capsule forms. Canopy has operations in seven countries across four continents. For more information, visit the company's website at www.canopygrowth.com.
As a Canadian regulated licensed producer, CannTrust™ (OTC: CNTTF) brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. CannTrust currently operates a 50,000 square foot state-of-the-art hydroponic facility in Vaughan, Ontario, as well as the recently completed 250,000 square foot Phase 1 redevelopment of its 430,000 square foot Niagara Greenhouse Facility. CannTrust™ is committed to research and innovation, as well as contributing to the growing body of evidence-based research regarding the use and efficacy of cannabis. For more information, visit the company's website at www.canntrust.ca.
Capstone Turbine (CPST)
Capstone Turbine (NASDAQ: CPST) develops, manufactures, markets and services microturbine technology solutions for use in stationary distributed power generation applications worldwide. The company's suite of offerings includes microturbine units, subassemblies, components and various accessories for applications, including cogeneration comprising combined heat and power ("CHP") and integrated CHP, as well as combined cooling, heat and power; and renewable energy, natural resources, and critical power supply. Its microturbines are also used as battery charging generators for hybrid electric vehicle applications. For more information, visit the company's website at www.capstoneturbine.com.
Care.com (NYSE: CRCM) is committed to solving the complex care challenges that impact families, caregivers, employers, and care service companies. Care.com is the world's largest online destination for finding and managing family care, with 15.0 million families and 11.4 million caregivers across more than 20 countries, including the U.S., UK, Canada and parts of Western Europe, and approximately 1.3 million employees of corporate clients having access to Care.com services. Spanning child care to senior care, pet care, housekeeping and more, Care.com provides a sweeping array of services for families and caregivers to find, manage and pay for care or find employment. For more information, visit the company's website at www.care.com.
Castle Brands (ROX)
Castle Brands (NYSE: ROX) develops, markets, imports, and sells beverage alcohol products in the United States and internationally. Its product categories include rum, whiskey, liqueurs, vodka, tequila, wine, and other spirits, as well as ginger beer and ready-to-drink cocktails. The company offers its products under the Jefferson's®, Goslings® Rums, Knappogue Castle Whiskey®, Clontarf® Irish Whiskey, Pallini® Limoncello, Boru® Vodka, Stormy Ginger Beer, Brady's® Irish Cream, The Arran Malt® Single Malt Scotch Whisky, The Robert Burns Scotch Whisky and Machrie Moor Scotch Whisky brands through a network of wholesale distributors and state-operated agencies. Castle Brands was incorporated in 2009 and is based in New York, New York. For more information, visit the company's website at www.castlebrandsinc.com.
CECO Environmental (CECE)
CECO Environmental (NASDAQ: CECE) ("CECO") is a global provider of engineered technologies and solutions to the energy, environmental, and industrial segments, targeting specific niche-focused end markets through an attractive asset-light business model. CECO helps companies expand their business with safe, clean, environmentally-friendly and more efficient solutions through providing innovative technology and application expertise. The company's brands, technologies and solutions are comprised of leading-edge technologies in specific niche global end markets, including natural gas turbine power, refinery & petrochemical engineered cyclones and mid-stream energy pipeline gas transmission. For more information, visit the company's website at www.cecoenviro.com.
Cellectar Biosciences (CLRB)
Cellectar Biosciences (NASDAQ: CLRB) is developing phospholipid drug conjugates ("PDCs") designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers, even sites of metastases. Cellectar's lead therapeutic PDC, CLR 131, has been designated as an orphan drug by the US FDA and is being evaluated in a phase 1 clinical study in patients with refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of B-cell malignancies. Cellectar's product pipeline also includes two preclinical PDC chemotherapeutic programs, CLR 1700 and CLR 1900, as well as partnered assets include PDCs from multiple R&D collaborations. For more information, visit the company's website at www.cellectar.com.
Celsius Holdings (CELH)
Celsius Holdings (NASDAQ: CELH) is a global company with a proprietary, clinically proven formula for its brand CELSIUS®. Celsius Holdings, Inc. has a corporate mission to become the global leader of a branded portfolio which is proprietary, clinically proven or innovative in its category, and offers significant health benefits. CELSIUS®' original line comes in seven flavors and is also available in single serve powdered packets. CELSIUS®' new natural line is available in six flavors that are naturally caffeinated and naturally sweetened. For more information, visit the company's website at www.celsiusholdingsinc.com.
Cemtrex (NASDAQ: CETX) is an international diversified industrial and manufacturing company that provides a wide array of solutions to meet modern technology challenges. Cemtrex provides manufacturing services of advanced custom engineered electronics design and manufacturing services, comprehensive industrial services, monitoring instruments for industrial processes and environmental compliance, and systems for controlling particulates, hazardous gases, emissions of greenhouse gases, and other regulated pollutants. The company is also engaged in the development of its own proprietary IoT and wearable devices. For more information, visit the company's website at www.cemtrex.com.
Century Casinos (CNTY)
Century Casinos (NASDAQ: CNTY) operates as a worldwide casino entertainment company focused primarily on investing in, developing and operating regional mid-size casinos. In addition to gaming establishments, the company's endeavors include developing and operating related lodging, restaurant, horse racing, and entertainment facilities. It owns and operates casinos in North America and Poland; a racetrack and entertainment center in Canada; and pari-mutuel off-track betting network in southern Alberta, Canada. The company also manages cruise ship-based casinos and a casino in Aruba; and provides gaming services in Argentina. For more information, visit the company's website at www.cnty.com.
CEVA (NASDAQ: CEVA) licenses signal processing platforms and artificial intelligence processors. The company partners with semiconductor companies and OEMs worldwide to create power-efficient, intelligent and connected devices for a range of end markets including mobile, consumer, automotive, industrial and IoT. CEVA's ultra-low-power IPs for vision, audio, communications and connectivity include comprehensive DSP-based platforms for LTE/LTE-A/5G baseband processing in handsets, infrastructure and machine-to-machine devices, advanced imaging, computer vision and deep learning for any camera-enabled device, audio/voice/speech and ultra-low power always-on/sensing applications for multiple IoT markets. CEVA also offers intellectual property for bluetooth, Wi-Fi and serial storage. For more information, visit the company's website at www.ceva-dsp.com.
Chaparral (OTC: CHPE) is an independent oil and natural gas exploration and production company headquartered in Oklahoma City. Founded in 1988, Chaparral is a leading Mid-Continent operator with focused operations in Oklahoma's highly economic STACK Play, where it has approximately 110,000 net acres and more than 3,500 potential drilling locations primarily in Kingfisher, Canadian and Garfield counties. The company has potential total production reserves of more than 1 billion barrels of oil equivalent and more than 350,000 net surface acres in the Mid-Continent region. For more information, visit the company's website www.atchaparralenergy.com.
Charles & Colvard (CTHR)
Charles & Colvard (NASDAQ: CTHR) manufactures, markets and distributes moissanite jewels and finished jewelry featuring moissanite worldwide. The company is the original creator and leading source of Forever One™, Forever Brilliant® and Forever Classic™ moissanite gemstones for fine jewelry. Moissanite is unique, available in three color grades and produced from silicon carbide crystals. Charles & Colvard Created Moissanite® is sold with a Limited Lifetime Warranty to wholesale distributors, manufacturers, retailers, shopping networks, and designers as loose stones or set in variety of quality metal setting options. The company also sells direct to consumers through its wholly owned operating subsidiary, charlesandcolvard.com, LLC and through third-party marketplaces. For more information, visit the company's website at www.charlesandcolvard.com.
ChromaDex (NASDAQ: CDXC) leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary health and wellness consumer products and ingredient technologies that promote healthy longevity. In addition to consumer product and ingredient technologies units, the company also has business units focused on natural product fine chemicals (known as "phytochemicals"), and product regulatory and safety consulting. With relationships with universities and research institutions, the company is able to discover and license early-stage, IP-backed ingredient technologies. For more information, visit the company's website at www.chromadex.com.
Clarus (NASDAQ: CLAR) designs, manufactures and markets outdoor engineered equipment and apparel for climbing, mountaineering, backpacking, skiing, and various other outdoor recreation activities in the United States and internationally. The company's products are primarily sold under the Black Diamond®, Sierra® and PIEPS® brand names through specialty and online retailers, distributors and original equipment manufacturers throughout the U.S. and internationally. Clarus Corporation was founded in 1957 and is headquartered in Salt Lake City, Utah. For more information, visit the company's website at www.claruscorp.com.
Cogentix Medical (CGNT)
Cogentix Medical (NASDAQ: CGNT) is a global medical device company that designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand. The company's innovative products provide users with efficient and cost-effective endoscope turnover while increasing patient safety. The company also commercializes the Urgent® PC Neuromodulation System, an FDA-cleared device that delivers percutaneous tibial nerve stimulation for the office-based treatment of overactive bladder ("OAB"). Additionally, the company offers Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. The company is headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom. For more information, visit the company's website www.cogentixmedical.com.
CohBar (OTCQX: CWBR) is a biotech company engaged in the research and development of mitochondria-based therapeutics ("MBTs") to treat various diseases associated with aging and metabolic dysfunction. MBTs originate from a discovery made by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts primarily focus on the development of these mitochondrial-derived peptides ("MDPs") into clinically applicable MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including obesity, nonalcoholic steatohepatitis ("NASH"), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. The company and its founders have discovered more than 100 MDPs to date. For additional company information, please visit www.cohbar.com.
Compass Diversified (CODI)
Compass Diversified (NYSE: CODI) owns and manages a diverse family of established North American middle market businesses. The company maintains controlling ownership interests in each of its subsidiaries to maximize its ability to impact long-term cash flow generation and value. The company provides both debt and equity capital for its subsidiaries. CODI utilizes the cash flows generated by its subsidiaries to invest in the long-term growth of the company and to make cash distributions to its shareholders. For more information, visit the company's website at www.compassequity.com.
Contango Oil & Gas Company (MCF)
Contango Oil & Gas Company (NYSE: MCF) is a Houston, Texas-based, independent energy company engaged in the acquisition, exploration, development, exploitation and production of crude oil and natural gas offshore in the shallow waters of the Gulf of Mexico and in the onshore Texas and Rocky Mountain regions of the United States. For more information, visit the company's website at www.contango.com.
Control4 (NASDAQ: CTRL) is a global provider of smart home solutions including automation and networking systems for homes and businesses. The company's innovative solutions offer personalized control of lighting, music, video, comfort, security, communications, and more into a unified smart home system. By unlocking the potential of connected devices, Control4 makes networks more robust, entertainment systems easier to use, homes more comfortable and energy efficient, and provides families more peace of mind. Leveraging a professional channel that includes over 5,500 custom integrators, retailers, and distributors authorized to sell the full-line of Control4 products, Pakedge branded networking solutions and Triad branded speakers, Control4 is delivering intelligent solutions for consumers, major consumer electronics companies, hotels, and businesses around the world. Control4 is now available in approximately 100 countries. For more information, visit the company's website at www.control4.com.
Cooper-Standard Holdings (CPS)
Cooper-Standard Holdings (NYSE: CPS) is a global supplier of systems and components for the automotive industry. Products include rubber and plastic sealing, fuel and brake lines, fluid transfer hoses and anti-vibration systems. Headquartered in Novi, Michigan, Cooper-Standard employs approximately 32,000 people globally and operates in 20 countries around the world. For more information, visit the company's website at www.cooperstandard.com.
Cosmos Holdings (COSM)
Cosmos Holdings (COSM) is a pharmaceutical wholesaler with offices and warehouses in Thessaloniki, Greece and in Harlow, UK. The company develops, markets, distributes, and sells over-the-counter medicines, and branded & generic pharmaceutical products wellness, and cosmetic products. The company has a trans-European network of over 110 clients and vendors which expands to 16 countries including: Germany, United Kingdom, Ireland, United Arab Emirates, Denmark, Italy, France, Singapore, Spain, Lebanon, Skopje, Jordan, Sweden, Poland, Netherlands, and Greece. For more information, visit the company's website at www.cosmosholdingsinc.com.
Cotinga Pharmaceuticals (COTQF)
Cotinga Pharmaceuticals (TSX-V: COT) (OTCQB: COTQF) is a clinical-stage pharmaceutical company that uses proprietary artificial intelligence ("AI") technologies to pursue a targeted and transformational method to treating cancer and other unmet medical needs. Cotinga's CHEMSAS® technology fast-tracks the discovery and development of novel drug therapies. The company's lead compound, COTI‐2, has demonstrated in preclinical data that it could potentially improve the treatment of cancers with mutations in the p53 gene. COTI‐2 is being evaluated for the treatment of gynecologic cancers and HNSCC in a phase 1 clinical trial. Cotinga has secured orphan drug status in the United States for COTI‐2 for the treatment of ovarian cancer. COTI-219, the company's second lead compound, is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function. COTI-219 is undergoing IND-enabling studies to support a regulatory submission in 2018. For more information, visit the company's website at www.cotingapharma.com.
Craft Brew Alliance (BREW)
Craft Brew Alliance (NASDAQ: BREW) ("CBA") is an independent craft brewing company that brews, brands and brings to market American craft beers. The company's portfolio combines the power of Kona Brewing Company, a national craft beer brand with an expanding stable of strong regional breweries and innovative lifestyle brands, including Appalachian Mountain Brewery, Cisco Brewers, Omission Brewing Co., Redhook Brewery, Square Mile Cider Co. and Widmer Brothers Brewing. CBA nurtures the growth and development of its brands through its state-of-the-art brewing and distribution capability, integrated sales and marketing infrastructure, and strong focus on partnerships, local community and sustainability. Formed in 2008, CBA is headquartered in Portland, Oregon, and operates breweries and brewpubs across the U.S. CBA beers are available in all 50 U.S. states and 30 different countries around the world. For more information, visit the company's website www.craftbrew.com.
Crius Energy (CRIUF)
Crius Energy (OTC: CRIUF) is one of the largest independent energy retailers in the United States, providing electricity, natural gas and solar products to more than 950,000 residential and commercial customers. The company connects with energy customers through an innovative family-of-brands strategy and multi-channel marketing approach. The result is a broad, well-differentiated platform that minimizes risk while providing customers with unique and customized brand experiences. For more information, visit the company's website at www.criusenergy.com.
Cronos Group (PRMCF)
Cronos Group (TSX-V: MJN) (OTC: PRMCF) is a globally diversified and vertically integrated cannabis company operating across four continents. The company runs two wholly-owned Canadian Licensed Producers regulated under Health Canada's Access to Cannabis for Medical Purposes Regulations: Peace Naturals Project Inc. in Ontario, and Original BC Ltd. in British Columbia. Additionally, Cronos has two international production and distribution platforms, Cronos Israel and Cronos Australia. Through an exclusive distribution agreement, Cronos has access to over 12,000 pharmacies in Germany as the company focuses on building an international brand portfolio and developing disruptive intellectual property. For more information, visit the company's website at www.thecronosgroup.com.
Crown Crafts (CRWS)
Crown Crafts (NASDAQ: CRWS) designs, markets and distributes infant, toddler and juvenile consumer products. Its product line includes crib and toddler bedding, bathing accessories, reusable and disposable bibs, and disposable placemats, floor mats, toilet seat covers and changing mats. The company's operating subsidiaries consist of Crown Crafts Infant Products, Inc. in California and Hamco, Inc. in Louisiana. Crown Crafts is among America's largest producers of infant bedding, toddler bedding and bibs. The company's products include licensed and branded collections, as well as exclusive private label programs for certain of its customers. For more information, visit the company's website at www.crowncrafts.com.
Cryoport (NASDAQ: CYRX) is a global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities. The company serves the biopharmaceutical market with logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. The company's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, and university researchers. The company also serves the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with cold chain logistics and client support, make the company an end-to-end cold chain logistics partner. For more information, visit the company's website at www.cryoport.com.
CTI BioPharma (CTIC)
CTI BioPharma (NASDAQ: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. For more information, visit the company's website at www.ctibiopharma.com.
CTS (NYSE: CTS) designs and manufactures products that sense, connect and move and supplies these products to OEMs in the aerospace, communications, defense, industrial, information technology, medical and transportation markets. The company manufactures sensors, actuators and electronic components in North America, Europe and Asia. For more information, visit the company's website at www.ctscorp.com.
Cutera (NASDAQ: CUTR) is a medical device company that designs, develops, manufactures, markets and services laser and other energy-based aesthetics systems for practitioners worldwide. Since 1998, the Brisbane, California-based company has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. Cutera's products address a wide range of face and body medical aesthetic application with results that drive patient satisfaction and practice growth. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating. For more information, visit the company's website at www.cutera.com.
CV Sciences (CVSI)
CV Sciences (OTC: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences has primary offices and facilities in San Diego, California and Las Vegas, Nevada. The company also operates its own PlusCBD Oil™ brand. For more information, visit the company's website at www.cvsciences.com.
Cyclacel Pharmaceuticals (CYCC)
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company's transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in BRCA positive patients with advanced solid cancers. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For more information, visit the company's website at www.cyclacel.com.
CymaBay Therapeutics (CBAY)
CymaBay Therapeutics (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. For more information, visit the company's website at www.cymabay.com.
CynergisTek (NYSE: CTEK) is a cybersecurity and information management consulting firm dedicated to serving the healthcare industry. CynergisTek offers specialized services and solutions to help organizations achieve privacy, security, compliance, and document output management goals. Since 2004, the company has served as a partner to hundreds of healthcare organizations and is dedicated to supporting and educating the industry by contributing to relevant industry associations. The company has been named in numerous research reports as one of the top firms that provider organizations select for privacy and security and was received the 2017 Best in KLAS award for Cyber Security Advisory Services. For more information, visit the company's website at www.cynergistek.com.
Cypress Semiconductor (CY)
Cypress Semiconductor (NYSE: CY) is an international provider of advanced embedded system solutions for innovative automotive, industrial, smart home appliances, consumer electronics and medical products. The company's microcontrollers, analog ICs, wireless and USB-based connectivity solutions and reliable, high-performance memories help engineers design differentiated products and bring them to market quickly. Cypress is committed to providing customers with the quality support and development resources which enables them to disrupt markets by creating new product categories in record time. For more information, visit the company's website at www.cypress.com.
Daqo New Energy (DQ)
Daqo New Energy (NYSE: DQ) is a manufacturer of high-purity polysilicon for the global solar PV industry. Founded in 2008, the low-cost producer of high-purity polysilicon and solar wafers primarily sells its products to solar cell and solar module manufacturers. Daqo New Energy has built a manufacturing facility that is technically advanced and highly efficient with a nameplate capacity of 12,150 metric tons in Xinjiang, China. The company also operates a solar wafer manufacturing facility in Chongqing, China. For more information, visit the company's website at www.dqsolar.com.
Daré Bioscience (DARE)
Daré Bioscience (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive health. Daré currently has two product candidates in clinical development. The first is Ovaprene™, a non-hormonal monthly contraceptive ring intended to provide protection over multiple weeks between menses. The second is SST-6007 a potential treatment for Female Sexual Arousal Disorder. SST-6007 incorporates sildenafil, the same active ingredient in Viagra®, in a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, leading to a potential improvement in genital arousal response and overall sexual experience. For more information, visit the company's website at www.darebioscience.com.
Darling Ingredients (DAR)
Darling Ingredients (NYSE: DAR) is the world's largest publicly-traded developer and producer of sustainable natural ingredients from edible and inedible bio-nutrients, creating a wide range of ingredients and specialty products for customers in the food, pet food, pharmaceutical, feed, industrial, fuel, bioenergy, and fertilizer industries. With operations on five continents, the company collects and transforms all aspects of animal by-product streams into broadly used and specialty ingredients, such as gelatin, edible fats, feed-grade fats, animal proteins and meals, plasma, pet food ingredients, organic fertilizers, yellow grease, fuel feedstocks, green energy, natural casings and hides. For more information, visit the company's website at www.darlingii.com.
Data I/O (DAIO)
Since 1972 Data I/O (NASDAQ: DAIO) has developed innovative solutions to enable the design and manufacture of electronic products for automotive, industrial/Internet-of-Things, consumer electronics, markets and their programming center and contract manufacturing partners. The company's customers manufacture hundreds of millions of products each year using Data I/O programming solutions to reliably, securely, and cost-effectively deliver their Intellectual Property into programmable devices. Data I/O's expertise in programmable integrated circuits, global supply chain processes, factory integration and IP management and protection are backed by a global network of Data I/O support and service providers to ensure customer success. For more information, visit the company's website at www.dataio.com.
Delcath Systems (DCTH)
Delcath Systems (OTC: DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. The company's proprietary product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS), is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The company has commenced a global phase 3 FOCUS clinical trial for patients with hepatic dominant ocular melanoma and plan to initiate a registration trial for intrahepatic cholangiocarcinoma ("ICC") in the fall of 2017. The company's Delcath Hepatic CHEMOSAT® Delivery System for Melphalan ("CHEMOSAT") has been commercially available in Europe since 2012. For more information, visit the company's website at www.delcath.com.
Delta Apparel (DLA)
Delta Apparel (NYSE: DLA) is an international design, marketing, manufacturing, and sourcing company that features a diverse portfolio of lifestyle basic and branded activewear apparel, headwear and related accessories along with its operating subsidiaries, M. J. Soffe, LLC, Junkfood Clothing Company, Salt Life, LLC and Art Gun, LLC. The company specializes in selling casual and athletic products across distribution tiers, including specialty stores, boutiques, department stores, mid-tier and mass chains, and the U.S. military. Additionally, the company's products are made available direct-to-consumer on its websites. The company's operations are located throughout the United States, Honduras, El Salvador, and Mexico, and it employs approximately 7,800 people worldwide. For more information, visit the company's website at www.deltaapparelinc.com.
Denny's (NASDAQ: DENN) is the franchisor and operator of one of America's largest franchised full-service restaurant chains, based on the number of restaurants. As of December 27, 2017, Denny's had 1,735 franchised, licensed, and company restaurants around the world including 128 restaurants in Canada, Puerto Rico, Mexico, New Zealand, Honduras, the Philippines, Costa Rica, Dominican Republic, the United Arab Emirates, Guam, Curaçao, El Salvador, Guatemala, and the United Kingdom. For more information, visit the company's website at www.investor.dennys.com.
Depomed (NASDAQ: DEPO) is a specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors through commercializing innovative products for pain and neurology related disorders. Depomed currently markets three medicines focused on neuropathic pain and migraine through its neurology and pain businesses. The company's emerging specialty business is focused on orphan drug indications and areas of unmet medical need. Depomed is headquartered in Newark, California. For more information, visit the company's website at www.depomed.com.
Digi International (DGII)
Digi International (NASDAQ: DGII) is a global provider of business and mission-critical Internet of Things ("IoT") and M2M products and services. Digi helps its customers create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security, unyielding reliability and quality performance. Since being founded in 1985, the company has helped its customers connect over 100 million things. For more information, visit the company's website at www.digi.com.
Digital Ally (DGLY)
Digital Ally (NASDAQ: DGLY) specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, commercial fleets, and consumer use. Digital Ally's complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide. For more information, visit the company's website at www.digitalallyinc.com.
Digital Turbine (APPS)
Digital Turbine (NASDAQ: APPS) connects top mobile operators, OEMs and publishers with app developers and advertisers worldwide at the convergence of media and mobile communications. Its comprehensive mobile delivery platform powers frictionless user acquisition and engagement, operational efficiency and monetization opportunities. Digital Turbine's technology platform has been adopted by more than 30 mobile operators and OEMs worldwide, and has delivered more than one billion app preloads for tens of thousands advertising campaigns. The company is headquartered in Austin, Texas, with global offices in Durham, Mumbai, San Francisco, Singapore, Sydney and Tel Aviv. For more information, visit the company's website at www.digitalturbine.com.
Diversified Restaurant Holdings (SAUC)
Diversified Restaurant Holdings (NASDAQ: SAUC) operates as a restaurant company in the United States. The company operates Buffalo Wild Wings Grill & Bar franchised restaurants, which primarily offer chicken wings, boneless wings, and other items, including chicken tenders, flatbreads, popcorn shrimps, specialty hamburgers and sandwiches, wraps, soft tacos, appetizers and salads. The company seeks to generate cash, reduce debt and leverage its strong franchise operating capabilities for future growth. For more information, visit the company's website at www.diversifiedrestaurantholdings.com.
DMC Global (BOOM)
DMC Global (NASDAQ: BOOM) operates in two sectors: industrial infrastructure and oilfield products and services. The industrial infrastructure sector is served by DMC's NobelClad business, the world's largest manufacturer of explosion-welded clad metal plates, which are used to fabricate capital equipment utilized within various process industries and other industrial sectors. The oilfield products and services sector is served by DynaEnergetics, an international developer, manufacturer and marketer of advanced explosive components and systems used to perforate oil and gas wells. For more information, visit the company's website at www.dmcglobal.com.
Dolphin Entertainment (DLPN)
Dolphin Entertainment (NASDAQ: DLPN) is an independent entertainment marketing and premium content development company. Through its recent acquisition of 42West, the company delivers strategic marketing and publicity services to film studios, independent and digital content providers, actors, directors, producers and recording artists. 42West was listed as one of the top four most powerful PR firms of any kind in the United States by the New York Observer in December 2017. Additionally, the company's content production business is an established independent producer committed to distributing premium film and digital entertainment primarily targeting the family and young adult markets. For more information, visit the company's website at www.dolphinentertainment.com.
DSP Group (DSPG)
DSP Group (NASDAQ: DSPG) is a global provider of wireless chipset solutions for converged communications. Delivering semiconductor system solutions with software and hardware reference designs, the company empowers OEMs/ODMs, consumer electronics (CE) manufacturers and service providers to cost-effectively develop new products with fast time to market. DSP Group provides a broad portfolio of wireless chipsets integrating DECT/CAT-iq, ULE, Wi-Fi, PSTN, HDClear™, video and VoIP technologies. The company enables converged voice, audio, video and data connectivity across diverse mobile, consumer and enterprise products – from mobile devices, connected multimedia screens, and home automation & security to cordless phones, VoIP systems, and home gateways. For more information, visit the company's website at www.dspg.com.
Dynatronics (NASDAQ: DYNT) designs, manufactures, distributes, markets and sells advanced-technology medical devices, treatment tables and rehabilitation equipment as well as thousands of products and supplies. The company provides these physical medicine and rehabilitation products primarily to physical therapists, chiropractors, athletic trainers and sports medicine practitioners. For more information, visit the company's website at www.dynatronics.com.
Eastside Distilling (EAST)
Eastside Distilling (NASDAQ: EAST) is a producer of high-quality, award-winning spirits crafted from natural ingredients. Eastside Distilling's product line includes Burnside Bourbon, West End American Whiskey, Goose Hollow Reserve, Below Deck Rums, Portland Potato Vodka, Hue-Hue Coffee Rum and a distinctive line of fruit infused spirits. The company is also a majority owner of Big Bottom Distilling and the Redneck Riviera Whiskey Co. The company has been operating in Portland, Oregon since 2008. For more information, visit the company's website at www.eastsidedistilling.com.
eGain (NASDAQ: EGAN) provides cloud-based customer engagement software solutions worldwide. eGain's customer engagement solutions power digital transformation for leading brands. The company's cloud applications for social, mobile, web, and contact centers help clients deliver connected customer journeys in an omnichannel world. For more information, visit the company's website at www.egain.com.
Eldorado Resorts (ERI)
Eldorado Resorts (NASDAQ: ERI) is a casino entertainment company that owns and operates twenty properties in ten states, including Colorado, Florida, Iowa, Louisiana, Mississippi, Missouri, Nevada, Ohio, Pennsylvania and West Virginia. Collectively, Eldorado's properties feature approximately 600 table games, over 7,000 hotel rooms and 21,000 slot machines and VLTs. For more information, visit the company's website at www.eldoradoresorts.com.
Elk Petroleum (EKPTF)
Elk Petroleum (OTC: EKPTF) is an oil and gas company specializing in Enhanced Oil Recovery ("EOR"). The company has assets in the Rocky Mountains, located in one of the richest onshore oil regions of the USA. Elk's strategy is focused on applying proven EOR technologies to mature oil fields, which significantly de-risks the company's strategy of finding and exploiting oil field reserves. For more information, visit the company's website at www.elkpet.com.
EMCORE (NASDAQ: EMKR) provides advanced mixed-signal optics products that provide the foundation for today's high-speed communication network infrastructures and cutting-edge defense systems. The company's optical chips, components, subsystems and systems enable broadband and wireless providers to continually enhance their network capacity, speed and coverage. EMCORE's optical components and systems serve a broad array of applications including cable television, fiber-to-the-premise networks, telecommunications, wireless infrastructure, satellite RF fiber links, navigation systems and military communications. The company has fully vertically-integrated manufacturing capability through its Indium Phosphide ("InP") wafer fabrication facility at its headquarters in Alhambra, California. For more information, visit the company's website at www.emcore.com.
Energous (NASDAQ: WATT) is the developer of WattUp®, an award-winning, wire-free charging technology aimed to renew the way consumers and industries charge and power electronic devices at home, in the office, in the car and beyond. WattUp is a radio frequency ("RF") based charging solution that delivers intelligent, scalable power via radio bands, similar to a Wi-Fi router. WattUp differs from older wireless charging systems in that it delivers contained power, at a distance, to multiple devices — thus resulting in a wire-free experience that saves users from having to remember to plug in their devices. For more information, visit the company's website at www.energous.com.
Enphase Energy (ENPH)
Enphase Energy (NASDAQ: ENPH) is a global energy technology company that delivers simple, innovative and reliable energy management solutions that advance the worldwide potential of renewable energy. The company sells its microinverter systems primarily to distributors, as well as directly to large installers through original equipment manufacturers and strategic partners. Enphase has shipped approximately 16 million microinverters, and approximately 700,000 Enphase residential and commercial systems have been deployed in more than 100 countries. For more information, visit the company's website at www.enphase.com.
EnSync (NYSE: ESNC) is creating innovative distributed energy resource ("DER") systems and Internet of energy ("IOE") control platforms. The company uses an electrical infrastructure that prioritizes the use of all available resources, such as renewables, energy storage and the utility grid. As project developer, the company provides load analysis, system design consulting, and technical and financial modeling to ensure energy systems are sized and optimized to meet customers' objectives. EnSync Energy's IOE control platform adapts easily to ever-changing generation and load variables, as well as changes in utility prices and programs, ensuring the means to make or save money behind-the-meter, while concurrently providing utilities the opportunity to use DERs for an array of grid enhancing services. In addition to direct system sales, the company also provides power purchase agreements. For more information, visit the company's website at www.ensync.com.
EnviroLeach Technologies (EVLLF)
EnviroLeach Technologies (OTCQB: EVLLF) is a technology company and near-term gold producer that focuses on developing and marketing hydrometallurgy solutions to the mining and electronic waste sectors. Using its proprietary non-cyanide, water-based, near neutral pH treatment process, EnviroLeach extracts precious metals from ores, concentrates, and E-Waste using only FDA approved additives to ambient temperature water. EnviroLeach's technology is backed by the momentum of a staff of scientists and engineers, tens of thousands individual assays, independent validations and strategic partners. For more information, visit the company's website at www.enviroleach.com.
Evofem Biosciences (EVFM)
Evofem Biosciences (NASDAQ: EVFM) is a biotechnology company that develops and anticipates commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company was founded in 2015 and is based in San Diego, California. For more information, visit the company's website at www.evofem.com.
Evoke Pharma (EVOK)
Evoke Pharma (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs for the treatment of gastrointestinal ("GI") disorders and diseases. The company is developing Gimoti, a novel formulation of metoclopramide for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus. Gimoti was designed to provide systemic delivery of metoclopramide through nasal administration. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. For more information, visit the company's website at www.EvokePharma.com.
Evolution Petroleum (EPM)
Evolution Petroleum (NYSE: EPM) develops and produces petroleum reserves within known oil and gas reservoirs in the U.S., with a focus on maximizing value per share. The company's principal asset is its interest in a CO2 enhanced oil recovery project in Louisiana's Delhi Field. For more information, visit the company's website at www.EvolutionPetroleum.com.
Eyegate Pharmaceuticals (EYEG)
Eyegate Pharmaceuticals (NASDAQ: EYEG) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate Ocular Bandage Gel ("OBG") is being evaluated in a pilot study for corneal re-epithelialization following photorefractive keratectomy ("PRK") surgery. EyeGate OBG is classified as a Class 2 medical device, and Eyegate intends to pursue U.S. regulatory clearance via the FDA's De Novo 510(k) pathway. The company's second product, EGP-437, integrates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through a proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in late-stage clinical trials evaluating the product in treatment of both anterior uveitis and pain and inflammation following cataract surgery. For more information, visit the company's website at www.eyegatepharma.com.
Eyenovia (NASDAQ: EYEN) is a late-stage biopharmaceutical company engaged in developing a pipeline of ophthalmology products in the United States. The company is building its portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. The company has three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. The company is advancing its two lead assets for glaucoma and mydriasis into phase 3 clinical programs and preparing registration studies for a third OTC product for dry eye. For more information, visit the company's website at www.eyenoviabio.com.